Back to Awarded Treatment Trials


Awarded Trial: 03T-459

Grant ID

03T-459

Illness

Schizophrenia

Primary Drug/Intervention

Celecoxib

Primary Dosage

400mg/day

Secondary Drug Intervention

Risperidone

Secondary Dosage

6mg/day

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Zhang

Sample Size

250

Duration of Study Period for Each Subject

24 weeks

Outcome Measurements

PANSS, BPRS, SANS, ICG, WCST, N-back Test, WMS-R, CPT, WAIS-R, FSIQ, SAS, AIMS, MANOVAs

Results

250 cases of first-episode (up to 2 years) were randomized to risperidone alone or risperidone plus celecoxib for 12 weeks. The celecoxib group showed a significant reduction in total PANSS, general psychopathology subscore, negative symptoms subscore, and HAMD total score.

Publication

N/A

Link

N/A

PI Name

Xiang Zhang

Degree

MD

Center

Department of Clinical Psychology

Institution

Beijing Hui-Long-Guan Hospital

Address

Xi San Qi, Hai Dian District

City or Town

Beijing

State or Province

N/A

Zip or Postal Code

100096

Country

China

Email Address

zhangxy9@yahoo.com